Loading...
XNYS
AVNS
Market cap597mUSD
Jun 10, Last price  
12.91USD
1D
2.14%
1Q
-11.58%
Jan 2017
-65.09%
IPO
-67.52%
Name

Avanos Medical Inc

Chart & Performance

D1W1MN
P/E
P/S
0.87
EPS
Div Yield, %
Shrs. gr., 5y
-0.68%
Rev. gr., 5y
-0.28%
Revenues
688m
+2.15%
1,659,900,0001,684,000,0001,677,500,0001,672,100,0001,574,400,0001,592,300,000611,600,000652,300,000697,600,000714,800,000744,600,000820,000,000673,300,000687,800,000
Net income
-392m
L+534.47%
142,400,000152,600,000154,600,00027,100,000-426,300,00039,800,00079,300,00057,500,000-45,900,000-27,200,0006,300,00050,500,000-61,800,000-392,100,000
CFO
101m
+210.80%
139,600,000202,600,000223,800,000147,900,00097,600,000188,800,000144,200,000-145,600,000-74,500,000-2,500,00087,300,00090,900,00032,400,000100,700,000
Earnings
Jul 29, 2025

Profile

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
IPO date
Oct 21, 2014
Employees
4,044
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
687,800
2.15%
673,300
-17.89%
820,000
10.13%
Cost of revenue
332,700
320,800
400,600
Unusual Expense (Income)
NOPBT
355,100
352,500
419,400
NOPBT Margin
51.63%
52.35%
51.15%
Operating Taxes
(17,000)
2,000
14,700
Tax Rate
0.57%
3.51%
NOPAT
372,100
350,500
404,700
Net income
(392,100)
534.47%
(61,800)
-222.38%
50,500
701.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
(12,800)
(19,100)
(43,800)
BB yield
1.75%
1.83%
3.42%
Debt
Debt current
20,300
34,200
19,000
Long-term debt
185,400
228,800
308,500
Deferred revenue
Other long-term liabilities
4,400
10,000
23,500
Net debt
98,000
175,300
199,800
Cash flow
Cash from operating activities
100,700
32,400
90,900
CAPEX
(17,800)
(17,800)
(19,300)
Cash from investing activities
(27,500)
21,600
(135,400)
Cash from financing activities
(49,100)
(94,200)
56,700
FCF
428,800
390,700
387,200
Balance
Cash
107,700
87,700
127,700
Long term investments
Excess cash
73,310
54,035
86,700
Stockholders' equity
(751,100)
(341,400)
(288,400)
Invested Capital
1,754,200
1,809,600
1,861,900
ROIC
20.88%
19.09%
22.10%
ROCE
35.21%
23.63%
26.23%
EV
Common stock shares outstanding
46,000
46,600
47,300
Price
15.92
-29.02%
22.43
-17.11%
27.06
-21.95%
Market cap
732,320
-29.94%
1,045,238
-18.34%
1,279,938
-24.04%
EV
830,320
1,220,538
1,479,738
EBITDA
400,600
398,600
467,100
EV/EBITDA
2.07
3.06
3.17
Interest
12,200
15,000
10,000
Interest/NOPBT
3.44%
4.26%
2.38%